Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday

L. Scarzella, M. Delsedime, B. Ferrero, C. Giangrandi, L. Priano, M. Rizzone, B. Bergamasco

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The Long Term Dopa Syndrome (LTDS) is one of the main problems in the management of advanced parkinsonian patients. A transient L-Dopa withdrawal (Drug Holiday, DH) can be useful to improve the drug response after DH, even if this approach presents risks due to patient akinesia. We tried to verify if Apomorphine sc administration during DH (DH with Apomorphine, DHA) can: a) reduce the risks connected with DH; b) maintain the benefits of DH; c) standardize the duration of DH. Twenty-five parkinsonian patients with LTDS were treated with Apomorphine sc during DH (14 days). No patient had any severe side effects. The follow-up at 180 days, conducted using the Unified Parkinson's Disease Rating Scale, demonstrated a significant improvement in the clinical conditions of about 70% of the patients, allowing a 27.1% reduction in daily L-dopa dosage. DHA can represent a valid therapeutical approach for parkinsonian patients with LTDS.

Original languageEnglish
Pages (from-to)163-170
Number of pages8
JournalJournal of Neural Transmission, Supplement
Issue number45
Publication statusPublished - 1995

Fingerprint

Holidays
Apomorphine
Pharmaceutical Preparations
Dihydroxyphenylalanine
Therapeutics
Levodopa
Parkinson Disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Scarzella, L., Delsedime, M., Ferrero, B., Giangrandi, C., Priano, L., Rizzone, M., & Bergamasco, B. (1995). Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday. Journal of Neural Transmission, Supplement, (45), 163-170.

Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday. / Scarzella, L.; Delsedime, M.; Ferrero, B.; Giangrandi, C.; Priano, L.; Rizzone, M.; Bergamasco, B.

In: Journal of Neural Transmission, Supplement, No. 45, 1995, p. 163-170.

Research output: Contribution to journalArticle

Scarzella, L, Delsedime, M, Ferrero, B, Giangrandi, C, Priano, L, Rizzone, M & Bergamasco, B 1995, 'Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday', Journal of Neural Transmission, Supplement, no. 45, pp. 163-170.
Scarzella, L. ; Delsedime, M. ; Ferrero, B. ; Giangrandi, C. ; Priano, L. ; Rizzone, M. ; Bergamasco, B. / Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday. In: Journal of Neural Transmission, Supplement. 1995 ; No. 45. pp. 163-170.
@article{1e1fdaccd5f54b6b9291912264c253fd,
title = "Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday",
abstract = "The Long Term Dopa Syndrome (LTDS) is one of the main problems in the management of advanced parkinsonian patients. A transient L-Dopa withdrawal (Drug Holiday, DH) can be useful to improve the drug response after DH, even if this approach presents risks due to patient akinesia. We tried to verify if Apomorphine sc administration during DH (DH with Apomorphine, DHA) can: a) reduce the risks connected with DH; b) maintain the benefits of DH; c) standardize the duration of DH. Twenty-five parkinsonian patients with LTDS were treated with Apomorphine sc during DH (14 days). No patient had any severe side effects. The follow-up at 180 days, conducted using the Unified Parkinson's Disease Rating Scale, demonstrated a significant improvement in the clinical conditions of about 70{\%} of the patients, allowing a 27.1{\%} reduction in daily L-dopa dosage. DHA can represent a valid therapeutical approach for parkinsonian patients with LTDS.",
author = "L. Scarzella and M. Delsedime and B. Ferrero and C. Giangrandi and L. Priano and M. Rizzone and B. Bergamasco",
year = "1995",
language = "English",
pages = "163--170",
journal = "Journal of Neural Transmission, Supplement",
issn = "0303-6995",
publisher = "Springer Wien",
number = "45",

}

TY - JOUR

T1 - Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday

AU - Scarzella, L.

AU - Delsedime, M.

AU - Ferrero, B.

AU - Giangrandi, C.

AU - Priano, L.

AU - Rizzone, M.

AU - Bergamasco, B.

PY - 1995

Y1 - 1995

N2 - The Long Term Dopa Syndrome (LTDS) is one of the main problems in the management of advanced parkinsonian patients. A transient L-Dopa withdrawal (Drug Holiday, DH) can be useful to improve the drug response after DH, even if this approach presents risks due to patient akinesia. We tried to verify if Apomorphine sc administration during DH (DH with Apomorphine, DHA) can: a) reduce the risks connected with DH; b) maintain the benefits of DH; c) standardize the duration of DH. Twenty-five parkinsonian patients with LTDS were treated with Apomorphine sc during DH (14 days). No patient had any severe side effects. The follow-up at 180 days, conducted using the Unified Parkinson's Disease Rating Scale, demonstrated a significant improvement in the clinical conditions of about 70% of the patients, allowing a 27.1% reduction in daily L-dopa dosage. DHA can represent a valid therapeutical approach for parkinsonian patients with LTDS.

AB - The Long Term Dopa Syndrome (LTDS) is one of the main problems in the management of advanced parkinsonian patients. A transient L-Dopa withdrawal (Drug Holiday, DH) can be useful to improve the drug response after DH, even if this approach presents risks due to patient akinesia. We tried to verify if Apomorphine sc administration during DH (DH with Apomorphine, DHA) can: a) reduce the risks connected with DH; b) maintain the benefits of DH; c) standardize the duration of DH. Twenty-five parkinsonian patients with LTDS were treated with Apomorphine sc during DH (14 days). No patient had any severe side effects. The follow-up at 180 days, conducted using the Unified Parkinson's Disease Rating Scale, demonstrated a significant improvement in the clinical conditions of about 70% of the patients, allowing a 27.1% reduction in daily L-dopa dosage. DHA can represent a valid therapeutical approach for parkinsonian patients with LTDS.

UR - http://www.scopus.com/inward/record.url?scp=0028971701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028971701&partnerID=8YFLogxK

M3 - Article

SP - 163

EP - 170

JO - Journal of Neural Transmission, Supplement

JF - Journal of Neural Transmission, Supplement

SN - 0303-6995

IS - 45

ER -